| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.21▼ | 1.22▼ | 1.23▼ | 1.21▲ | 0.99▲ |
| MA10 | 1.22▼ | 1.24▼ | 1.24▼ | 1.20▲ | 0.77▲ |
| MA20 | 1.24▼ | 1.24▼ | 1.20▼ | 0.99▲ | 0.54▲ |
| MA50 | 1.25▼ | 1.19▲ | 1.19▲ | 0.70▲ | 2.10▼ |
| MA100 | 1.20▼ | 1.20▲ | 1.12▲ | 0.51▲ | 9.83▼ |
| MA200 | 1.20▲ | 1.06▲ | 0.89▲ | 1.39▼ | 60.43▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.010▼ | -0.002▼ | 0.005▲ | 0.273▲ |
| RSI | 32.742▼ | 43.384▼ | 48.297▼ | 64.890▲ | 50.567▲ |
| STOCH | 7.011▼ | 0.926▼ | 29.879 | 50.062 | 69.830 |
| WILL %R | -100.000▼ | -100.000▼ | -69.697 | -35.526 | -22.186▲ |
| CCI | -132.821▼ | -124.863▼ | -72.492 | 72.465 | 145.575▲ |
|
Tuesday, January 07, 2020 05:09 AM
ADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA ...
|
|
Friday, December 20, 2019 04:00 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its ...
|
|
Friday, December 20, 2019 02:27 AM
It is doubtless a positive to see that the Advaxis, Inc. (NASDAQ:ADXS) share price has gained some 98% in the last three months. But will that repair the damage for the weary investors who have owned ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/01/20 | 1.29 | 1.35 | 1.20 | 1.21 | 3,968,500 |
| 16/01/20 | 1.23 | 1.29 | 1.19 | 1.28 | 5,219,400 |
| 15/01/20 | 1.12 | 1.17 | 1.09 | 1.17 | 2,412,900 |
| 14/01/20 | 1.20 | 1.21 | 1.06 | 1.15 | 4,227,700 |
| 13/01/20 | 1.25 | 1.30 | 1.20 | 1.22 | 4,367,000 |
| 10/01/20 | 1.18 | 1.27 | 1.13 | 1.21 | 5,300,634 |
| 09/01/20 | 1.19 | 1.24 | 1.12 | 1.16 | 4,303,300 |
| 08/01/20 | 1.24 | 1.32 | 1.15 | 1.23 | 8,187,000 |
| 07/01/20 | 1.46 | 1.48 | 1.22 | 1.30 | 39,919,413 |
| 06/01/20 | 1.14 | 1.17 | 1.01 | 1.07 | 5,772,300 |
|
|
||||
|
|
||||
|
|